Eli Lilly stock jumps as GLP-1 sales widen Novo lead
Eli Lilly shares rose up to 7% after Q2 revenue jumped 48% to $22.97B, beating Wall Street by over $2B. Mounjaro and Zepbound totaled $14.87B, about 65% of revenue. Lilly lifted its 2026 outlook to $85B-$87B. Novo Nordisk also raised guidance, but U.S.-listed shares fell after Wegovy pill sales missed expectations.
How this was made
The 30-second read
Why it matters
LLY’s beat and raised 2026 outlook are direct catalysts for re-rating, while NVO’s U.S. pill sales miss creates a near-term sentiment headwind even with an outlook improvement.
Market read
This is a same-day, results-driven relative-performance story: LLY’s guidance raise and product beats versus NVO’s U.S. oral miss.
What to watch
The article emphasizes revenue and product sales but does not detail margin, supply constraints, or longer-term competitive trial outcomes that could change the durability of the lead.
Background
The piece frames a divergence between the two dominant obesity-drug manufacturers after LLY’s Q2 results and NVO’s U.S. oral Wegovy pill performance.
Ticker impact
Eli Lilly reported Q2 revenue up 48% to $22.97B, beat by over $2B, and raised 2026 revenue outlook to $85B-$87B.
Near-term bullish bias, with follow-through risk if investors fade the beat or focus on competitive oral GLP-1 progress.
The article discloses multiple fresh, decision-relevant datapoints: revenue/earnings beats, product-level sales strength, and an explicit 2026 outlook raise.
Novo Nordisk improved its full-year outlook, but its U.S.-listed shares fell 6% after Wegovy pill sales narrowly missed expectations.
Choppy to mildly bearish near-term as investors weigh the miss against the outlook raise.
The text provides a concrete U.S.-listed price reaction and a specific product miss, but lacks the magnitude of the outlook change and the exact sales figures.
Market effects
Reinforces that investors are differentiating obesity-drug leaders by delivery format, potentially shifting relative valuation between injectable and oral GLP-1 strategies.
U.S. ADR reaction highlights that U.S. demand and product mix are driving near-term relative performance.
Competitive read-through for global GLP-1 market share, with U.S. oral launch execution influencing broader sentiment.
Counterpoint
The raised LLY outlook could already be partially priced, and the market may quickly refocus on sustainability of growth rates rather than the beat.
Key entities
- companyEli Lilly and Company
Reported Q2 results driven by Mounjaro and Zepbound and raised 2026 revenue outlook.
- companyNovo Nordisk
Improved full-year outlook but saw U.S.-listed shares fall after Wegovy pill sales narrowly missed expectations.
- productMounjaro
Tirzepatide for diabetes; revenue surged in the quarter.
- productZepbound
Tirzepatide for obesity in the U.S.; revenue grew strongly in the quarter.
- productWegovy
Obesity drug; U.S. pill sales narrowly missed expectations per the article.
